Thermis Chikungunya Vaccine Enters Phase III Trials- Major Breakthrough
Posted by
www.biotecnika.org
Themis's Vaccine for Chikungunya raises €40M in Series D round. In one
of the most extensive Series D Round for Biotech at Australia, Themis
Biosciences was successful in raising €40M to fund the Phase III
trials for its Chikungunya Vaccine. This round was co-led investors
like Farallon Capital and Hadean Ventures, Adjuvant Capital, aws
Gründerfonds, Omnes […]
The post Thermis Chikungunya Vaccine Enters Phase III Trials- Major
Breakthrough appeared first on BioTecNika .
https://www.biotecnika.org/2019/09/thermis-chikungunya-vaccine-enters-phase-iii-trials-major-breakthrough/
Biotech News
Subscribe to:
Post Comments (Atom)
Post a Comment